Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 12/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4753776 | 0.82 | GPR35 (0.68) | GPR35PTPN1PKMNPSR1RXFP1 | |
| SCHEMBL6808074 | 0.82 | GPR35 (0.42) | GPR35PTPN1PKMRXFP1ALDH1A1 | |
| SCHEMBL26626874 | 0.78 | GPR35 (0.48) | GPR35PTPN1PKMNPSR1RXFP1 | |
| SCHEMBL20894452 | 0.78 | GPR35 (0.48) | GPR35PTPN1PKMNPSR1RXFP1 | |
| SCHEMBL4582179 | 0.78 | GPR35 (0.54) | GPR35PTPN1TSHRALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL8935194 | 0.76 | GPR35 (0.52) | GPR35PTPN1TSHRALDH1A1HPGD | |
| SCHEMBL11804199 | 0.75 | GPR35 (0.48) | GPR35PTPN1PKMNPSR1RXFP1 | |
| SCHEMBL2727696 | 0.73 | GPR35 (0.66) | GPR35PTPN1PKMNPSR1RXFP1 | |
| SCHEMBL27029227 | 0.73 | GPR35 (0.44) | GPR35PTPN1TSHR | |
| SCHEMBL623043 | 0.72 | GPR35 (0.43) | GPR35PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118496197-A | Substituted thiophenecarboxamides, thiophenecarboxylic acids and derivatives thereof | 拜耳公司 | 2024-08-16 | — | — | CN | disclosed |
| EP-4285723-A2 | SUBSTITUTED THIOPHENE CARBOXAMIDES, THIOPHENE CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-12-06 | — | — | EP | disclosed |
| US-20230046892-A1 | SUBSTITUTED THIOPHENE CARBOXAMIDES, THIOPHENE CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-16 | — | — | US | disclosed |
| CN-115103840-A | Substituted thiophenecarboxamides, thiophenecarboxylic acids and derivatives thereof | 拜耳公司 | 2022-09-23 | — | — | CN | disclosed |
| WO-2021123051-A1 | SUBSTITUTED THIOPHENE CARBOXAMIDES, THIOPHENE CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-24 | — | — | WO | disclosed |
| US-20130190289-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-25 | — | — | US | disclosed |
| EP-2585447-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012006055-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | WO | disclosed |
| EP-1123291-A1 | PROCESS FOR PREPARING 3-(SUBSTITUTED PHENYL)-5-THIENYL OR FURYL)-1,2,4-TRIAZOLES AND NOVEL INTERMEDIATES UTILIZED THEREIN | Dow Agrosciences LLC (US) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000024738-A1 | PROCESS FOR PREPARING 3-(SUBSTITUTED PHENYL)-5-THIENYL OR FURYL)-1,2,4-TRIAZOLES AND NOVEL INTERMEDIATES UTILIZED THEREIN | DOW AGROSCIENCES LLC (US) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046892-A1 | SUBSTITUTED THIOPHENE CARBOXAMIDES, THIOPHENE CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | PGLS, TST, TPI1 | GPR35 2792/4885PTPN1 802/4885PKM 979/4885 |
| US-20130190289-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | SLC10A1, ACE, CEL | GPR35 2653/4885PTPN1 479/4885PKM 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.